HP163 as oral treatment of viral infection
- HP163 is ready for IND enabling pre-clinical development
- In-vivo studies in models of Zika-virus infection show single agent efficacy of HP163, blocking viral replication and inhibiting microencephaly
- AhR inhibitors show in-vitro efficacy against Dengue virus infection
- Efficacy against Covid-19 is being tested
- HP163 is protected by composition of matter patents.
Discovery of novel AhR inhibitors for treatment of cancer and viral infections
- Hercules is engaged in the discovery of further novel AhR inhibitors for treatment of solid tumors and of viral infections